


Product Name : Venetoclax
Cat. No. : PC-49764
CAS No. : 1257044-40-8
Molecular Formula : $C_{45}H_{50}ClN_7O_7S$
Molecular Weight : 868.45
Target : Bcl-2
Solubility : 10 mM in DMSO



Biological Activity

Venetoclax (ABT-199, GDC-0199) is a highly potent, selective and orally bioavailable **Bcl-2** inhibitor with K_i value of <0.01 nM.

Venetoclax (ABT-199) displays >4800-fold selectivity for Bcl-2 over Bcl-xL and Bcl-w, and displays no measurable activity at Mcl-1.

Venetoclax (ABT-199) potently induces apoptosis in FL5.12-BCL-2 cells ($EC_{50}=261$ nM) and reduces tumor burden in chronic lymphocytic leukemia (CLL) primary samples ($EC_{50}=3$ nM).

Venetoclax (ABT-199) enhances efficacy of clinically relevant chemotherapy and immunotherapy drugs.

Venetoclax (ABT-199) exhibits binding to SARS-CoV-2 3C-like protease (3CLpro) active site in a virtual screen.

Venetoclax (ABT-199) reverses oxidative phosphorylation in acute myeloid leukemia cells (AML), in vitro and in vivo.

References

Souers AJ, et al. **Nat Med**. 2013 Feb;19(2):202-8.

Vogler M, et al. **Br J Haematol.** 2013 Oct;163(1):139-42.

Vandenberg CJ, et al. **Blood**. 2013 Mar 21;121(12):2285-8.

Vaillant F, et al. **Cancer Cell**. 2013 Jul 8;24(1):120-9.

Caution: Product has not been fully validated for medical applications. Lab Use Only!